Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of JMJD1C target genes in LN-229 glioblastoma cells.

ABSTRACT: JMJD1C shows ubiquitous expression and is often downregulated in tumor entities compared to healthy tissues.JMJD1C inhibit growth of the glioblastoma cell line LN-229. Here, JMJD1C knockdown leads to malignant progression in the glioblastoma cell line LN-229.

ORGANISM(S): Homo sapiens

PROVIDER: GSE166351 | GEO | 2021/02/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identification of JMJD1C target genes in LN-229 glioblastoma cells.

Project description:Identification of JMJD1C target genes in LN-229 glioblastoma cells.

| PRJNA700586 | ENA

RNA sequencing analysis of LN-229-shControl and LN-229-shMOB2 cells

Project description:RNA sequencing analysis of LN-229-shControl and LN-229-shMOB2 cells

| PRJNA579353 | ENA

Expression data from WIF1 induced LN-229 (GBM cell line)

Project description:Glioblastoma is the most aggressive primary brain tumor in adults and due to the invasive nature it cannot be completely removed. We have recently shown that the WNT inhibitory factor 1 (WIF1), a secreted inhibitor of WNTs, is downregulated in glioblastoma and acts as strong tumor suppressor. In search of a mediator for this function differential gene expression profiles of WIF1-expressing cells were performed. MALAT1, a long non-coding RNA and key positive regulator of invasion, emerged as the top downregulated gene. Indeed, knock-down of MALAT1 reduced migration in glioblastoma cells, without effect on proliferation. LN-229 cells induced with Doxocyclin to express WIF1 were compared to the non-induced control (two biological replicates each)

2015-02-23 | E-GEOD-58525 | biostudies-arrayexpress

Effect of IDH1 mutation induced by doxycycline on gene expression during VSVΔ51 infection in LN-229-TRE-R132H glioblastoma cells

Project description:To investigate whether IDH1 mutation influence the effects of oncolytic virus VSVΔ51, we transduced doxycycline-inducible IDH1-R132H lentiviruses into LN-229 to establish the LN-229-TRE-R132H cell line. We then performed gene expression profiling analysis using data obtained from RNA-seq of LN-229-TRE-R132H cells infected with or without VSVΔ51 in the presence or absence of IDH1 mutation induced by doxycycline.

2023-09-19 | GSE208634 | GEO

Effect of Vortioxetine treatment on gene expression of LN-229 glioblastoma cells over time

Project description:The atypical antidepressant Vortioxetine represents the most effective neuroactive drug with anti-glioblastoma efficacy across glioblastoma patient samples and model systems. To closer examine the temporal dynamics of Vortioxetine, we performed in-depth transcriptomic profiling of LN-229 cells following Vortioxetine treatment. We performed gene expression profiling analysis using data obtained from RNA-seq across 6 different time points during the 24 hours following Vortioxetine treatment.

2024-07-29 | GSE214968 | GEO

Comparative proteomic analysis of EV-derived from glioblastoma (LN 229 cell line) and healthy human astrocytes, neurons and endothelial brain cells

Project description:This study aims to identify EV-derived glioblastoma biomarkers through a comparative mass spectrometry-based bottom-up proteomic analysis of glioblastoma LN-229 cell line and healthy human neurons, astrocytes, and endothelial brain cells (HEBC). The work investigates cancer cells' communication with the healthy brain environment

2024-09-03 | PXD055487 |

Digital RNA with pertUrbation of Genes (DRUG-Seq) of LN-229 glioblastoma cells treated with 20 different drugs at two time points

Project description:DRUG-Seq is a miniatruized and multiplexed RNA-Seq protocol described in Ye et al., 2018 (https://www.nature.com/articles/s41467-018-06500-x) To determine transcriptional changes upon drug perturbation in LN-229 glioblastoma cells, we profiled 20 drug responses across two time-points (6 and 22 hours) by DRUG-Seq

2024-07-29 | GSE214965 | GEO

Effect of Vortioxetine treatment on gene expression of LN-229 glioblastoma cells over time

Project description:Effect of Vortioxetine treatment on gene expression of LN-229 glioblastoma cells over time

| PRJNA887807 | ENA

Jmjd1c

Project description:Jmjd1c

| PRJNA304620 | ENA

JMJD1C knockdown (H9_CT2_JMJD1C-KD_Microarray_JW)

Project description:It has been recently reported that the pluripotency factor OCT4, the early neural inducing factor NR2F2, and the pluripotency-associated miRNA miR-302 are linked in a regulatory circuitry that critically regulate both pluripotency and neural differentiation of human embryonic stem cells (hESCs). We show here that JMJD1C, a H3K9 demethylase expressed in undifferentiated hESCs, plays a key role in the regulatory circuitry. hESCs with JMJD1C knockdown (KD) retain the state of self-renewal and pluripotency, but express lower miR-302c than control hESCs. JMJD1C directly binds to the miR-302 promoter in hESCs and reduces H3K9 methylation on the promoter. Upon withdrawal of bFGF (an inhibitor of neural initiation) from a defined culture medium, the KD, but not control, hESCs differentiate into neural progenitors within three days – the fastest ever reported, accompanied by rapid increase of NR2F2 expression. A miR-302c analogue or an inhibitor of H3K9 methylation reduces neural induction from the KD hESCs, whereas a miR-302c inhibitor promotes hESC differentiation. Together, our findings suggest that JMJD1C plays a central role in control of neural differentiation from hESCs, which involves sustained miR-302c expression, and that inhibition of JMJD1C is sufficient to rapidly induce neural progenitors from hESCs in the defined medium depleted of bFGF. This is also the first evidence, to our knowledge, for epigenetic modification of miR-302 in hESCs. 6 human ES cell lines were used in this microarray assay. Each line has two replicates.

2013-12-24 | E-GEOD-46485 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data